CytoSorbents Corp (CTSO) hit operating cash flow breakeven and lifted product gross margin to 75% in Q3 2026, while outlining an early 2027 de novo submission for DrugSorb ATR.
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the third quarter ended September 30, 2026, recent business highlights, and provides a regulatory update.
Detailed price information for Telix Pharm Ltd (TLPPF) from The Globe and Mail including charting and trades.
Detailed price information for Cytosorbents Cor (CTSO-Q) from The Globe and Mail including charting and trades.
Detailed price information for Cytosorbents Cor (CTSO-Q) from The Globe and Mail including charting and trades.
Newsfile Press Release.
Detailed price information for Cytosorbents Cor (CTSO-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.